Inventor
XAVIER LIGNEAU
Inventor
FR
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds25%
C07BGeneral methods of organic chemistry13%
PatentTitleYear
12,582,648Method for treating central nervous system disorders using dopamine D3 partial agonists202612,134,608Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands202412,059,416Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof202411,306,069Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands202211,229,632Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to BIOPROJET SOC CIV (4)· patent assignee history
2022–2026Based in FR· patent location history
2026Patents assigned to BIOPROJET PHARMA (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIOPROJET SOC CIV | 4 | 2022–2024 |
| BIOPROJET PHARMA | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| FR | 5 | 2022–2026 |